Isabelle J. Carroll

Isabelle J. Carroll

Auto-generated profile, based on publicly available information

Isabelle J. Carroll

Department of internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Circulation
Verified
Journal Article
Closed access
HKHan Kyul Kim
Han Kyul Kim
AFAyumi Fukazawa
Ayumi Fukazawa
SSScott A. Smith
Scott A. Smith
MMMasaki Mizuno
Masaki Mizuno
BRBeverly A. Rothermel
Beverly A. Rothermel
WVWanpen Vongpatanasin
Wanpen Vongpatanasin
BACKGROUND: Recent studies have highlighted the deleterious role of high phosphate intake in hypertension via sympathetic overactivation, yet the underlying mechanisms remain unclear. Dietary phosphate loading triggers physiologic release of FGF23 (fibroblast growth factor–23) from the bone to maintain phosphate homeostasis. Both FGF23 and FGF receptors (FGFRs) are present in the central nervous system, but their role in neural control of blood pressure during phosphate loading is unknown. We investigated central FGF23/FGFR signaling in high-phosphate diet–induced sympathetic dysregulation of blood pressure in rats. METHODS: FGF23 protein levels were measured by immunoprecipitation, immunoblotting, and immunohistochemistry. FGF23 translocation into the brain was determined by injecting infrared-labeled FGF23 intravenously into anesthetized Sprague-Dawley rats. Mean arterial pressure (MAP) and renal sympathetic nerve activity (RSNA) responses to hindlimb muscle contraction were measured in decerebrate Sprague-Dawley rats treated with either a normal 0.6% phosphate diet (NP) or a high 1.2% phosphate diet (HP) for 12 weeks before and after intracerebroventricular (ICV) administration of FGFR signaling inhibitors. RESULTS: Excess phosphate intake significantly increased FGF23 protein levels in the brainstem (HP versus NP, P =0.009) and cerebrospinal fluid (HP versus NP, P <0.001). Peripheral injection of infrared-labeled FGF23 showed clear entry into the choroid plexus and medulla oblongata. ICV administration of PD173074, a pan-FGFR(1–4) inhibitor, significantly attenuated the heightened RSNA (Δ=84±53 versus 32±25% [ P <0.0001]) and MAP (Δ=35±14 versus 9±7 mm Hg [ P <0.0001]) responses to muscle contraction in HP animals, but did not affect the RSNA and MAP responses during stimulation in NP animals (ΔRSNA=40±29 versus 30±22% and ΔMAP=18±13 versus 13±9 mm Hg before versus after ICV injection). ICV injection of BLU9931, a relatively selective FGFR4 inhibitor, also decreased the responses in HP rats only (∆RSNA=112±70 versus 65±46% [ P =0.006] and ∆MAP=41±14 versus 20±14 mm Hg [ P <0.0001] before versus after ICV injection). However, ICV administration of AZD4547, a FGFR1–3 inhibitor, and C-terminal FGF23 peptide, a competitive inhibitor of FGF23/FGFR/α-Klotho complex formation, did not alter the responses in either NP or HP animals. CONCLUSIONS: Our data reveal a novel pathophysiologic paradigm of high-phosphate diet–induced sympathoexcitation and hypertension by FGF23 crossing into the brain, possibly acting via FGFR4.

31 July 2025 in Health Affairs Scholar
Verified
Journal Article
Open access
JLJoshua M Liao
Joshua M Liao
PCPaula Chatterjee
Paula Chatterjee
YZYueming Zhao
Yueming Zhao
ICIsabelle J Carroll
Isabelle J Carroll
DBDanielle S Browne
Danielle S Browne
ANAmol S Navathe
Amol S Navathe
Introduction: Individuals dually eligible for insurance through both Medicaid and Medicare (“duals”) have more comorbidities, higher costs, and poorer outcomes compared to other groups. Unfortunately, policy and care redesign initiatives suffer from limited knowledge about ambulatory care patterns among duals. Methods: Using 2022 Medicare fee-for-service claims and other sources of clinician and geographic data, we described care patterns for ambulatory services among dual vs non-duals. Our sample consisted of 967 820 dual and 4 600 486 non-dual individuals receiving a total of 67 122 906 ambulatory services from 106 545 practices and 815 827 clinicians. Results: We found that duals received fewer ambulatory, in particular subspecialty, services than non-duals, while duals received slightly more services through primary care physicians and advanced practice professionals. Among duals, most services were provided in office rather than federally qualified health centers or rural health clinics by a disproportionally small number of geographically dispersed practices and clinicians. High-dual practices and clinicians differed from non-high dual counterparts with respect to multiple characteristics. Conclusion: These differences highlight the opportunity to improve access and outcomes among duals by targeting policy and practice changes toward certain groups and clinicians.

26 May 2025 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PNPhilong Nguyen
Philong Nguyen
JLJoshua Ellis Lewis
Joshua Ellis Lewis
ICIsabelle J Carroll
Isabelle J Carroll
JWJoshua Wang
Joshua Wang
MGMbinui Ghogomu
Mbinui Ghogomu
JSJuquan Song
Juquan Song
Previous studies have linked preexisting substance use disorders (SUDs) to adverse postoperative outcomes in burn patients, yet their impact on opioid use remains unclear. This retrospective cohort study compares the effects of various substances on opioid use after burns and aims to analyze the risks and whether they differ among substances. The TriNetX database was queried for burn patients aged 18 years and older with preexisting alcohol, cannabis, or tobacco use disorders, who were placed in their respective cohorts. These patients were matched to a nonsubstance use disorder cohort using propensity score matching based on demographics, mental health, pain syndromes, and burn severity. The measured outcomes assessed were opioid use, wound infection, wound disruption, and postprocedural pain. Risk ratios and 95% confidence intervals were calculated at 3 months and 12 months postburn. After matching, patients with preexisting SUDs had significantly higher risk ratios for prolonged opioid use, wound infections, and wound healing disruptions at both 3 and 12 months compared to matched patient control cohorts. Additionally, all patient cohorts also exhibited increased risk of postprocedural pain. Burn patients with preexisting SUDs face a significantly higher risk of prolonged opioid use and postoperative complications at both 3- and 12-month postburn injury. The alcohol cohort patients were associated with the greatest increase in opioid use and postoperative complications, while the tobacco patient cohort presented with the highest wound disruption rates at 3- and 12-months postburn.

10 September 2026 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
SDShanup Dalal
Shanup Dalal
ICIsabelle Carroll
Isabelle Carroll
WWWinnie S. Wang
Winnie S. Wang
SHSepedeh Hazrati
Sepedeh Hazrati
JMJane Mwangi
Jane Mwangi
AHArthur S. Hong
Arthur S. Hong
Background: Recurrent ascites is a debilitating complication of malignancy and cirrhosis that frequently leads to hospital admissions. Palliative care is well positioned to address symptom burden through both medical and procedural interventions. Objectives: To characterize healthcare utilization among patients requiring paracentesis and evaluate the feasibility, utilization, and safety of an outpatient palliative care procedure clinic. Methods: We conducted a needs assessment at Parkland Health (USA) by identifying patients followed by the palliative care team with stage IV malignancy or cirrhosis who were admitted for paracentesis between 2018 and 2023. Findings informed the development of an outpatient palliative care procedure clinic. A retrospective analysis of the first 12 months was performed, including patient characteristics, procedural outcomes, and symptom burden using the Palliative Care Outcome Scale (POS). A postimplementation satisfaction survey was administered to clinic staff after the pilot year. Results: A total of 493 patients accounted for 672 hospital admissions requiring paracentesis, with a median length of stay of eight days (interquartile range [IQR], 4–18). During the first year of the clinic, 19 patients underwent 44 outpatient paracenteses. Median age was 50 years (IQR, 43.5–60.5), 63% were female, and 84% had malignant ascites. No immediate procedural complications occurred during a 20-minute postprocedure observation period, and none were identified within seven days on chart review. Median fluid removal was 3500 mL (IQR, 2400–4050 mL). Baseline POS scores demonstrated substantial symptom burden (mean 17.3 ± 5.8). Staff satisfaction with clinic continuation and expansion was high (mean score 4.8/5). Conclusions: Patients with recurrent ascites experience substantial healthcare utilization and symptom burden. An outpatient palliative care procedure clinic appears feasible and safe in this pilot cohort. Larger studies are needed to confirm safety and evaluate effects on healthcare utilization and patient-centered outcomes.